Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Shuangcheng

Drug and asset intelligence for Shuangcheng with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
1
Stage
Development stage unavailable

Mechanism of action

Proton Pump Inhibitor

Recent signals(2)

RegulatoryJuly 28, 2026

FDA Grants Approval for Pantoprazole Sodium ANDA219973

The FDA has granted approval for the ANDA219973 application for Pantoprazole Sodium submitted by Shuangcheng.

StrategyJuly 5, 2026

FDA Grants Approval for Pantoprazole Sodium ANDA219973

The FDA has granted approval for ANDA219973, a generic version of Pantoprazole Sodium, submitted by Shuangcheng.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Shuangcheng

July 5, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Gastroenterology →
Gastroenterology · Proton Pump Inhibitor →
Proton Pump Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.